Sign in with Google
bullish
CSL Ltd (CSL AU): Weak Vaccine Sales Affect H1FY25 Performance; FY25 Guidance Maintained
315 Views12 Feb 2025 00:30
SUMMARY
- For H1FY25, CSL Ltd (CSL AU) reported net profit of $2.01B, up 6% YoY, missing estimate of $2.07B. Underlying profit (NPATA) grew 3% YoY to $2.07B.
- H1FY25 revenue increased 5% YoY to $8.48B. Solid performance from CSL Behring and CSL Vifor was partially offset by negative impact from CSL Seqirus.
- The company has reaffirmed FY25 underlying profit guidance of $3.2–3.3B at constant currency, up 10–13% YoY. Revenue growth is anticipated to be 5–7% YoY at constant currency.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- East Buy Holdings (1797 HK): Potential KWEB Deletion in June
- HEW: Doves Disappointed By Patience
- [Japan Activism] ISS Comes Out Supporting Orbis Against Tsuruha/Welcia Merger Ratio
- [Japan M&A] NTT (9432) Overpays To Buy Out NTT Data (9613) Minorities
- StubWorld: Geely Is (Mostly) Trading "Rich"; And May Still Bump Zeekr Terms
Top Unpaywalled Insights
More »- The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
- Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
- India-UK Free Trade Agreement: A New Era for India's Textile Industry
- The Rise of Quant Investing in Crypto w/ Truvius CEO Connor Farley | The New Barbarians #007
- New Research: Unlocking Quantitative Alpha in Cryptocurrency Markets
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- CSL Ltd (CSL AU): Weak Vaccine Sales Affect H1FY25 Performance; FY25 Guidance Maintained12 Feb 2025
- CSL Ltd (CSL AU): Double-Digit Sales and Profit Growth in H1FY24 Led by Immunoglobulin Franchise15 Feb 2024
- CSL Ltd (CSL AU): Banking on Strong Growth in Immunoglobulin Franchise on Record Plasma Collection16 Sep 2023
- CSL Ltd (CSL AU): FY23 Guidance Cut Drags Near-Term Prospect; Long-Term Growth Drivers Still Intact15 Jun 2023
x